GlobeNewswire Inc.··NaBoundless Bio Extends Cash Runway to Mid-2028 Amid BBI-940 Clinical Expansion
Boundless Bio reported $107.6M cash, narrowed 2025 net losses to $58.2M, and is advancing lead breast cancer candidate BBI-940 through Phase 2 trials.
BOLDbreast cancercash runway